Drug class
Angiopoietin-like protein 3 (ANGPTL3) inhibitor; fully human monoclonal antibody
Mechanism of action
Binds ANGPTL3 and inhibits its interaction with lipoprotein lipase and endothelial lipase, increasing triglyceride-rich lipoprotein clearance and reducing LDL cholesterol through LDL-receptor-independent pathways.
General use cases
- Adjunct to diet and other LDL-cholesterol-lowering therapies for patients aged 5 years and older with homozygous familial hypercholesterolaemia (HoFH); it is not indicated for general hypercholesterolaemia without HoFH
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
